about
Genomic and functional characterization of stellate cells isolated from human cirrhotic livers.Stage of cirrhosis predicts the risk of liver-related death in patients with low Model for End-Stage Liver Disease scores and cirrhosis awaiting liver transplantationAscites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management.Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cellsNoninvasive assessment of liver function.Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.Venous Thrombotic Events After Liver Transplantation.Use of artificial intelligence as an innovative donor-recipient matching model for liver transplantation: results from a multicenter Spanish study.Hepatocarcinoma cells stimulate the growth, migration and expression of pro-angiogenic genes in human hepatic stellate cells.Mannose-Binding Lectin-Deficient Donors Increase the Risk of Bacterial Infection and Bacterial Infection-Related Mortality After Liver Transplantation.Development of multiorganic calciphylaxis during teriparatide, vitamin D, and calcium treatment.Usefulness of liver stiffness measurement during acute cellular rejection in liver transplantation.Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes.Epidemiology, clinical characteristics, and outcome of invasive aspergillosis in renal transplant patients.Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition.Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after SVR in recurrent hepatitis C.Candida norvegensis fungemia in a liver transplant recipient.Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: regulation by cytokines and bacterial lipopolysaccharide.Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats.Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans.[Treatment of liver fibrosis].Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.Use of albumin in the management of patients with decompensated cirrhosis. An independent verdict.[The value of MELD in the allocation of priority for liver transplantation candidates].Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis.Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver.A new scoring system for prognostic stratification of patients with alcoholic hepatitis.Bradykinin attenuates hepatocellular damage and fibrosis in rats with chronic liver injury.Pilot study of living donor liver transplantation for patients with HCC exceeding Milan criteria (BCLC extended criteria).An objective definition for clinical suspicion of T-cell-mediated rejection after liver transplantation.Increased risk of portal vein thrombosis in patients with autoimmune hepatitis on the liver transplantation waiting list.Endoscopic management of bile leaks after liver transplantation: An analysis of two high-volume transplant centers.Mesenchymal stromal cells for immunomodulatory cell therapy in liver transplantation: One step at a time.Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C.Combined liver-kidney transplantation in patients with cirrhosis and chronic kidney disease.Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity.Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis.Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells.Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II.MIDODRINE &ALBUMIN for Preventing COMPLICATIONS IN PATIENTS WITH CIRRHOSIS AWAITING Liver transplantation
P50
Q33217368-87236B8C-1697-44F1-9BDF-F901F5FC4F96Q34254341-B3AEAF65-38FD-42B2-B990-4CDF78A4CCADQ35068045-DA4D3435-77B4-49E0-BC2D-92C6CA845B80Q35569812-4139F683-9AFF-4C65-83F7-D772738D8269Q38365125-2F389E18-D3F8-41A2-8A92-D6AF65BAEC72Q38607787-7DCAE9FF-ACC6-461F-9157-B02A5A8AD3DEQ39144613-727FFAE9-E953-4922-A154-AA2CB141ED60Q39179560-82F639D7-ACB2-4E7C-9A71-E05BCF9C2997Q39772282-91CE3D55-A6A1-4A7B-B8F9-FFE7AFB036B6Q40145824-30F5667F-4656-4348-B042-9EB9FBEF2069Q40742615-832CB502-2EBC-4FBC-9C5E-E12598878CFFQ40894137-0D117C73-6C93-4169-9C7D-EF4B845D22B2Q41584023-AAAA6435-751E-4245-B794-0021924EAB93Q41700108-A3B11074-E332-4906-A9F2-2FE18083D986Q41707732-E82D820B-E9EB-417D-B316-470D2A44ADCAQ41928194-ABA11F18-ACC8-49C7-BADE-69ECFEEC6E30Q42216716-3B4DB2C5-4CE2-403D-8F74-D186B76B987CQ42469681-BB14C20A-D5EE-4DAE-B286-D97FF956D9EBQ43078753-D9F6899C-93C9-4FDF-849D-1FFD56E35798Q43193400-73F5B5BC-B7B5-4532-A38E-E64E3BEEBFCCQ43300615-912864E1-2A36-498B-AA04-7B7774C4E9CCQ43851678-BB4F8C9E-3961-43D1-BA0C-96E4ECCE47EBQ44620391-02D7083D-366F-4436-B09F-99D15B65A70BQ45920379-FDC64D96-E6A2-4D5C-9A62-0D2B9EB1DF20Q46080216-833BCCAD-F8C2-43F9-B5A4-A189CD8433F9Q46213897-210CC94E-A00F-4FDA-B9E0-D67EDE69C6CEQ46415682-C2EEFF6E-D002-4CDA-8EE3-07683346DABCQ46869929-360EF658-16CF-4893-9DFF-818B69EA6663Q47579175-383A4971-2D77-46DA-91E2-B19E8B453807Q48153634-C3A03051-C7DF-44DF-8194-0119D5B50395Q48164883-EEDB6DA7-AC42-4361-9D0C-F4ACEB7E0295Q49602108-76821BC4-72A0-480F-9C51-A20BD35E09EEQ50209765-082795EB-402D-4122-AD03-A1469856C284Q50569264-5DC197F5-E84A-4298-9E59-D4532B0240B9Q50585803-01ABBF89-82B6-44B2-8947-2ACE697A848AQ50707448-3815501A-BCAD-4BBF-8961-AF27ECAED2C4Q51828724-42171DFE-3E4A-485D-96EA-AABA9BE27803Q54596371-BE9F951D-1F6E-4B81-9F27-707785FF11AEQ54765190-A3EBC3D8-61C6-4619-A9DA-8A1B3735007DQ56516206-7FD8550D-C06D-40DE-A438-E97891AC3163
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jordi Colmenero
@ast
Jordi Colmenero
@en
Jordi Colmenero
@es
Jordi Colmenero
@nl
Jordi Colmenero
@sl
type
label
Jordi Colmenero
@ast
Jordi Colmenero
@en
Jordi Colmenero
@es
Jordi Colmenero
@nl
Jordi Colmenero
@sl
prefLabel
Jordi Colmenero
@ast
Jordi Colmenero
@en
Jordi Colmenero
@es
Jordi Colmenero
@nl
Jordi Colmenero
@sl
P1053
J-7521-2017
P106
P21
P31
P3829
P496
0000-0001-6024-8479